Cellectis is a clinical-stage biotechnology company that develops cell and gene therapies using its proprietary gene editing platform, TALEN®. The company focuses on creating off-the-shelf Chimeric Antigen Receptor (CAR) T-cell therapies aimed at treating various cancers, particularly relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Cellectis operates globally and collaborates with strategic partners to enhance its research and development efforts, leveraging a strong intellectual property portfolio that includes numerous patents.
- Website
- www.cellectis.com
- Issuer profile
- All listings